Dear Pharma Pals,

This issue of Pharma Machines & Technology presents two exclusive interviews. One on the India CRO technology advantage with Binoy Gardi, Group CEO and MD, Veeda Lifesciences; and another one with Abdulla Azizov, First Deputy Minister of Health of the Republic of Uzbekistan and Chairman of the Pharmaceutical Industry Development Agency.

What kinds of data integration, interoperability, and infrastructure capabilities are essential for India to compete globally in clinical research? Binoy Gardi says: India’s next competitive advantage will depend on data infrastructure. We generate large volumes of clinical information, but too much of it remains locked in hospital systems, diagnostic centres, paper records, non-interoperable EMRs, and local workflows. Global sponsors cannot use data that cannot be standardized, governed, and audited.

Highlighting the potential of Veeda-Mango partnership, Binoy shares insights into the convergence of clinical expertise, AI, and data intelligence, and what will define India’s success as a global CRO innovation hub in the years ahead.

Abdulla Azizov positions Uzbekistan as a leading pharmaceutical gateway to Eurasia. The country is pursuing a comprehensive strategy focused on localization, innovation, international quality standards, and investment attraction. The Government actively supports technology transfer, contract manufacturing, workforce development, and the adoption of international regulatory standards, including EU GMP.

Tashkent Pharma Park, which is evolving into Bio Pharma City, is the flagship project supporting Uzbekistan’s vision of becoming a regional pharmaceutical hub.

Harjit Singh Dhaul
Publisher & Editor